文献速递头颈部肿瘤放疗

诱导化疗联合再程放疗对比单纯再程放疗治疗局部复发鼻咽癌:基于模型的分析

Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis.
PubMed 文献 · Radiother Oncol · 2023-09-09

该回顾性研究纳入3个肿瘤治疗中心2012至2020年间接受再程放疗的480例局部复发鼻咽癌患者,比较加用诱导化疗与单纯再程放疗或同步放化疗的总生存。全队列中加用诱导化疗与放疗 alone 或同步放化疗的总生存相似;在中间风险组(系数和0.9–1.6)中,诱导化疗联合再程放疗的总生存显著优于单纯再程放疗(P=0.03),经IPTW校正后仍观察到生存获益(P=0.031),低风险和高风险组无显著差异。

要点

  • 全队列中加用诱导化疗与单纯再程放疗(P=0.58)或同步放化疗(P=0.76)的总生存相似。
  • 中间风险组(系数和0.9–1.6)中诱导化疗联合再程放疗的总生存显著优于单纯再程放疗(P=0.03),IPTW校正后仍显著(P=0.031)。
  • 低风险组(系数和<0.9)和高风险组(系数和>1.6)中加用诱导化疗未见总生存显著差异。

核心结论

  • 在局部复发鼻咽癌中间风险组中,再程放疗前加用诱导化疗与总生存改善相关,而低风险组和高风险组无差异。
  • 原文指出需要前瞻性验证来证实这些发现。

研究设计与样本

  • 回顾性分析3个肿瘤治疗中心2012至2020年间接受再程放疗的480例局部复发鼻咽癌患者。
  • 采用Kaplan-Meier法计算总生存并用log-rank法比较,采用逆概率治疗加权(IPTW)匹配成对治疗组,采用Cox比例风险回归多因素分析识别总生存预测因素。
  • 风险分层模型由系数和计算的风险评分定义。

主要发现

  • 全队列中,加用诱导化疗与单纯放疗相比总生存相似(P=0.58),与同步放化疗相比总生存也相似(P=0.76)。
  • 基于显著预后因素构建并验证风险分层模型,因素及系数包括男性(0.6)、年龄≥60岁(0.9)、复发肿瘤大体肿瘤体积≥16 cc(0.7)和乳酸脱氢酶(LDH)比值≥0.5(0.4)。
  • 中间风险组(系数和0.9–1.6)中,诱导化疗联合再程放疗患者的总生存显著优于单纯再程放疗患者(P=0.03)。
  • 经IPTW校正多个潜在混杂变量后,仍观察到诱导化疗的生存获益(P=0.031)。
  • 低风险组(系数和<0.9)和高风险组(系数和>1.6)中,再程放疗前加用诱导化疗未显示总生存显著差异。

关键数值与推荐

  • 风险分层模型基于以下显著预后因素及其系数:男性(0.6)、年龄≥60岁(0.9)、复发肿瘤大体肿瘤体积≥16 cc(0.7)、LDH比值≥0.5(0.4)。
  • 中间风险组定义为系数和0.9–1.6,低风险组定义为系数和<0.9,高风险组定义为系数和>1.6。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要前瞻性验证来证实这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the role of additional induction chemotherapy (IC) prior to re-irradiation in locally recurrent nasopharyngeal carcinoma (lrNPC). METHODS: A total of 480 patients from three cancer treatment centers who received re-irradiation between 2012 and 2020 were retrospectively analyzed. Overall survival (OS) was determined using the Kaplan-Meier method and compared with log-rank method. Inverse probability of treatment weighting (IPTW) was performed to match the patients in pairwise treatment groups. Multivariate analysis using the Cox proportional hazards regression method identified predictors of OS. The risk stratification model was defined by the risk score calculated with the sum of coefficients. RESULTS: In the entire cohort, the addition of IC was associated with similar OS compared with radiotherapy alone (P = 0.58) or with concomitant chemoradiation (P = 0.76). A risk stratification model was constructed and validated based on significant prognostic factors (coefficient) including male (0.6), age ≥ 60 years (0.9), volume of recurrence gross tumor volume ≥ 16 cc (0.7), and lactate dehydrogenase (LDH)-ratio ≥ 0.5 (0.4). In the intermediate-risk group (sum of coefficient: 0.9---1.6), patients with IC plus re-irradiation had a significantly better OS than those who received re-irradiation (P = 0.03). After adjustments for several potentially confounding variables with IPTW, survival benefit of IC was also observed (P = 0.031). However, no significant difference in OS for the additional IC prior to re-irradiation was demonstrated in the low- (sum of coefficient: <0.9) and high-risk group (sum of coefficient: > 1.6). CONCLUSION: Additional IC prior to re-irradiation was associated with improved OS in the intermediate-risk group of lrNPC, whereas there was no difference for the low-risk and high-risk group. Prospective validation is required to validate these findings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yan W, Liu T, He M, et al. Induction chemotherapy plus re-irradiation versus re-irradiation alone in locally recurrent nasopharyngeal carcinoma: A model-based analysis. Radiother Oncol. 2023. PMID: 37678621. doi:10.1016/j.radonc.2023.109903

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。